Corporate Member Roster



 Corporate Member Plus Graphic Feb2016 

J&JMylanNovoSandozTakeda
Bonnie Shaul
Director, Managed Healthcare Payer Strategy
(847) 937-5397
bshaul@abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

ACADIA Pharmaceuticals Inc.
Mark Bubany
Senior Director Access, Pricing & Advocacy
(858) 863-1089
mbubany@acadia-pharm.com

At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders. Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.

Acorda Therapeutics, Inc. http://www.acorda.com
Steven Sandor
Vice President, Market Access
(914) 326-5373
ssandor@acorda.com

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda filed a New Drug Application (NDA) for its lead clinical product, Fampridine-SR, on January 30, 2009. Clinical trials of Fampridine-SR evaluated its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Alcon Laboratories, Inc. http://www.alconlabs.com
Dale R. Seibt
Director, Managed Markets
(817) 568-6064
dale.seibt@alcon.com

As a global leader in eye care, Alcon’s mission is to provide innovative products that enhance quality of life by helping people see better. Alcon offers the widest spectrum of eye care products in surgical, pharmaceutical and vision care across 180 markets and operations in 75 countries. Alcon is committed to making significant contributions to preserve, restore and enhance vision by addressing the world’s most pressing eye care needs in areas such as cataracts, glaucoma, retinal diseases, refractive errors, ocular allergies, dry eye, infection and inflammation. Headquartered in Fort Worth, Texas, Alcon has more than 24,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.

Jason Voegele
Senior National Managed Markets Director-West
(949) 233-0818
jason.voegele@alkermes.com

Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.

Doug Fernandes
VP, Payer Marketing & Strategic Pricing
(862) 261-7000
doug.fernandes@actavis.com

Allergan, Inc. is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care, obesity and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people’s lives. Driven by technology and innovation, Allergan addresses the needs of consumers across the world with over 8,000 employees worldwide, 4 world-class Research and Development facilities and 5 state-of-the-art manufacturing plants.

Amarin Pharma, Inc. http://www.amarincorp.com
Joseph Gilhooly
Senior Director, Managed Care
(908) 719-1315 x522
jgilhooly@yahoo.com

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Larry Green
Director, Global Scientific Communications
(805) 447-3010
lgreen@amgen.com

The world’s largest biotechnology company, Amgen Inc. discovers, develops, and delivers important human therapeutics based on advances in cellular and molecular biology including EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), NEUPOGEN® (Filgrastim), Neulasta® (pegfilgrastim), Enbrel® (etanercept), Kineret® (anakinra) and Sensipar® (cinacalcet HCl). Amgen’s dedication to science and innovation is driven by a commitment to serving patients.

Apobiologix, a division of ApoPharma USA www.apobiologix.com
James Van Lieshout
VP Market Access and Pharmacy Strategy
(303) 444-9102
jvanlies@apotex.com

Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 10,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies has approximately 5,500 employees. Extensive investments in Canadian facilities include over 3 million square feet in manufacturing and R&D facilities in Richmond Hill, Toronto, Etobicoke, Brantford, Windsor and Winnipeg. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 89 million prescriptions a year - the largest amount of any pharmaceutical company in this country

Argus Health Systems, Inc. http://www.argushealth.com
Kristy Cayot
Marketing Manager
(816) 843-5832
kristy.cayot@argushealth.com

Argus Health Systems, Inc., is the leading independent provider of health care information management services supporting commercial, Medicaid and Medicare Part D. Argus serves a wide range of clients and key health care organizations including managed care organizations, pharmacy benefit managers and pharmaceutical manufacturers. Argus was established in 1983, and by 1986 was a pioneer in electronic claims processing. Since then Argus has grown to become one of the largest pharmacy claims processors in the industry. In 2013, Argus processed more than 605 million claims, including one in five of all Medicare Part D claims nationwide. Argus is a wholly-owned subsidiary of DST Systems, Inc., headquartered in Kansas City, Mo. We also have customer relationships in every state in the country. Argus has been a catalyst for change in the pharmacy benefit management industry. Our unique business model is based on the values of integrity and honesty that frame our relationships with our clients. What we have offered our clients from the start—full disclosure, program control and aligned objectives—is now becoming the business model of choice. Our business model provides full disclosure and is transparent, with no fees or competing hidden business relationships. Consistent with our mission and values, Argus’ programs are fully auditable. Argus is free from industry bias and conflicts of interest—and has been recognized as an industry leader in these areas. Argus does not compete with our customers for business, act as a plan sponsor, nor do we own or have ownership in a mail order distribution facility. By not owning or operating a mail-service pharmacy, we have no reason to give advice regarding plan design that is biased toward a mail-service benefit. Such independence gives us the opportunity to be a leader in a fully transparent pharmacy benefit model for our customers and further the cause for industry transparency, reducing costs, and providing quality care.

Astellas Pharma US, Inc. http://www.us.astellas.com/
Steve Steinhagen

(847) 317-8880
steve.steinhagen@us.astellas.com

Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.

Avalere Health, LLC
Leigh Ann Bruhn
Director
(202) 459-6284
lbruhn@avalere.com

Avalere Health is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, business intelligence tools and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. For more information, visit avalere.com, or follow us on Twitter @avalerehealth.

Todd W. Michael
Director Marketing - US Payer & Reimbursement
(224) 940-5259
Todd.Michael@Baxalta.com

Baxalta Incorporated is a global biopharmaceutical leader developing, manufacturing and commercializing transformative therapies to treat orphan and underserved disease conditions in hematology, immunology and oncology. Baxalta spun-off from Baxter International Inc. on July 1, 2015. Baxalta has a solid foundation and our patient-focused strategy, disciplined financial management, transformative culture and people, position us well to drive profitable growth and enhance value for patients, customers and shareholders. Our targeted innovation strategy and cutting-edge science, combined with strategic partnerships, come together to spark discovery and deliver innovation for patients with limited treatment options.

Danelle Caldwell
Regional Account Executive
(248) 650-8411
danelle.caldwell@bayer.com

From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer HealthCare is a globally researching healthcare company.

Jay Newman
Senior Director, Payer & Channel Marketing
(781) 464-5909
jay.newman@biogen.com

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com

Boehringer Ingelheim Pharmaceuticals, Inc. http://www.boehringer-ingelheim.com
Kristen Binaso
Sr. Assoc Director, Patient Advocacy & Prof Relations
(203) 798-5758
kristen.binaso@boehringer-ingelheim.com

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors. In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales. For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

Bristol-Myers Squibb Company http://www.bms.com
Alma Howard
Director Midwest Region Value Access & Payment
(954) 240-1747
alma.howard@bms.com

Our company’s mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products. We pledge – to our patients and customers, to our employees and partners, to our shareholders and neighbors, and to the world we serve – to act on our belief that the priceless ingredient of every product is the honor and integrity of its maker. Aligned with our mission, Bristol-Myers Squibb Managed Markets team is dedicated to supporting the important role managed care plays in extending and enhancing human life.

Celgene Corporation http://www.celgene.com
George Malouly
Market Access
(310) 995-0175
gmalouly@celgene.com

Celgene is a global integrated biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies designed to treat cancer and immunoinflammatory diseases. Celgene is dedicated to work closely with health care providers to assure patients in need have safe access to our drugs. The Company is also proud of the important benefits that our therapies bring to patients, of the Company’s demonstrated commitment to rapidly advance its promising new therapies through development so many more patients can be helped, and of the breadth of its programs to ensure that no American is denied access as a result of lack of resources. The ongoing development of our broad and deep proprietary pipeline of immunomodulatory agents (IMiDs®), cell-signaling inhibitors, as well as cellular and tissue therapeutics may allow Celgene to provide physicians worldwide with a more comprehensive and integrated set of therapeutic solutions for managing complex human diseases.

Celldex Therapeutics http://www.celldex.com
Devin Rubin
Associate Director, Payer Marketing
(908) 323-2249
drubin@celldex.com

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.

Marc Claussen
Director, Market Access
(317) 773-0695
marc.claussen@chiesi.com

Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.

Collegium Pharmaceutical, Inc. www.collegiumpharma.com
Kevin Statz
Director, Marketing and Strategy
(781) 232-0742
kstatz@collegiumpharma.com

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. Collegium’s lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.

Gary A. Loeber
Principal
(847) 559-3817
gary.loeber@cvshealth.com

CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,900 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at www.cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at www.cvscaremark.com/newsroom.

Daiichi Sankyo, Inc. http://www.dsi.com
Tara Mautone
Director, Managed Markets Operations
(973) 944-2640
tmautone@dsi.com

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Japan-based Daiichi Sankyo Co., Ltd., one of the twenty largest pharmaceutical companies in the world and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo’s research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit www.dsus.com.

Jeff Vengley
VP Managed Markets & Trade
(510) 744-8585
jvengley@depomed.com

Depomed, Inc. is a specialty pharmaceutical company focused on products to treat pain and other central nervous (CNS) system conditions. The company’s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options patient populations that may be underserved by existing therapies. In addition, the company seeks to continue to leverage its innovative Acuform technology to generate a complementary stream of license revenue

Scott Sorenson
Director, Government
(704) 246-6646
ssorenson@biorx.net

Allen Waxman
Exec. VP and General Counsel Market Access/Law & Government Affairs
(201) 746-2750
allen_waxman@eisai.com

Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd., which was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia. Globally, most of Eisai’s sales are derived from treatments for central nervous system diseases and gastrointestinal disorders. Eisai has more than 7,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo and Osaka exchanges and in the United States under an American Depository Receipt with the ticker symbol of ESALY.

EMD Serono Inc. http://www.emdserono.com
John Neal
VP Marketing, Managed Markets
(781) 681-2040
john.neal@emdserono.com

EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.

Exelixis, Inc. www.exelixis.com
Michael McDole
Senior National Account Director
(303) 548-8949
mdmcdole@hotmail.com

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. Exelixis was founded and incorporated in 1994 and we are based in South San Francisco, California. Exelixis is dedicated to improving the care of, and outcomes for patients with cancer.

Jody H. Allen
VP, Clinical Account Management, Health Plans
(804) 967-7122
jody_allen@express-scripts.com

At Express Scripts, we help make the use of prescription drugs safer and more affordable. It's been our mission since 1986, when a group of healthcare advocates began applying the rigors of scientific research to the pharmacy benefit. With the country facing hundreds of billions of dollars of prescription-related waste each year from costly drug, pharmacy and health choices, our mission remains as relevant as ever. We are passionate about gleaning insights from data and translating those insights into solutions. We test and learn our way toward the most comprehensive set of solutions to drive out prescription-related waste and help improve health outcomes. We provide best-in-class pharmacy benefit management (PBM) services and industry-leading home delivery and specialty pharmacy services for our diverse client base.

Fresenius Medical Care North America http://www.fmcna.com
Amanda Holtz
Executive Assistant
(781) 699-9045
amanda.holtz@fmc-na.com

Providing direct renal services to over 167,000 ESRD patients, Fresenius Medical Care (FMCNA) is the largest provider of renal therapy services and products in the United States. We manufacture and distribute the leading dialysis products and equipment and other dialysis_related supplies. Fresenius Medical Cared North Americas pharmaceutical offering includes, Velphor®, Venofer® & Phoslyra®.

Genentech Inc. http://www.gene.com
Fran Molettieri
Director, Regional General Manager Team
(650) 225-4552
molettieri.francis@gene.com

Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.

Gilead Sciences, Inc. http://www.gilead.com
Bruce Pfaff
Associate Director, SP Trade Operations West
(510) 908-3535
bruce.pfaff@gilead.com

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. Visit Gilead on the World Wide Web at www.gilead.com.

Fran M. Kochman
Director, Advocacy & Alliance Development
(860) 668-9013
fran.m.kochman@gsk.com

GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.

Health Information Designs, LLC http://www.hidllc.com
Kathleen Sabo
Director of Business Development & Marketing
(334) 466-3031
kathleen.sabo@hidesigns.com

Health Information Designs (HID) is a pharmacy services company that provides a comprehensive suite of prior authorization (PA) solutions to health plans and pharmacy benefit managers for promoting compliance monitoring, adherence, and criteria management. HID's clinical professionals -- pharmacists, physicians, and nurses -- know the industry, our products, and our clients. Our combined total of over 650 years of pharmacy experience provides the strong clinical foundation on which we build our solutions.

Incyte Corporation http://www.incyte.com
Douglas Kylander
Director, Access, Reimbursement and Distribution
(302) 498-5740
dkylander@incyte.com

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. The company’s first commercial product, Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, is approved by the FDA to treat two rare blood disorders--first approved in November 2011 Jakafi received a subsequent U.S. approval in December 2014. To learn about Jakafi, please visit www.Jakafi.com

Insulet Corporation insulet.com
Steve Bledsoe
Director, Managed Care
(978) 600-7000
sbledsoe@insulet.com

Intarcia Therapeutics www.intarcia.com
Aria Cohen
Executive Director, Payer Strategy & Programs
(617) 936-2593
aria.cohen@intarcia.com

Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories. Our near-term goal is to enhance treatment outcomes for patients with type 2 diabetes by improving efficacy, continuous administration, and tolerability of drug therapies.

Intercept Pharmaceuticals
Keith White
US Head, Marketing Access and Reimbursement

keith.white@interceptpharma.com

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing our proprietary bile acid chemistry. The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

Johnson & Johnson Health Care Companies http://www.jnj.com
William J. Johnson
National Account Director
(847) 726-9962
wjohnso2@its.jnj.com

Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.

Joe Duarte
Director of Market Access
(858) 472-2721
jduarte@kaleopharma.com

Kaléo is a pharmaceutical company dedicated to putting a new generation of life-saving personal medical products in your hands. We believe you are the expert on how your medical condition impacts your life and so we bring you into the product development process. Each kaléo product combines an established drug with an innovative delivery platform with the goal of achieving superiority over the current standard of care and cost effectiveness. Ultimately, the goal is to provide peace of mind you can carry with you. Kaléo applies rigorous selection criteria to identify areas where its patient-centric approach and proprietary technology will offer superior solutions. The company only proceeds to an active development program once it has established that incremental clinical and economic benefit is achievable.

Lexicon Pharmaceuticals http://www.lexgen.com/
Alexander Santini
Head, Market Access & Channel Mgmt
(908) 360-4704
asantini@lexpharma.com

Lilly USA, LLC http://www.lilly.com
John H. Poulin
Director, Professional Relations
(317) 277-8173
jhpoulin@lilly.com

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Magellan Rx Management www.magellanrx.com
Steve Michurski
SVP, PBM Trade Relations
(480) 624-9339
smichurski@magellanhealth.com

Todd Killian
Global Vice President, Market Access
(314) 654-3335
todd.killian@mallinckrodt.com

Mallinckrodt is a global specialty pharmaceutical company. Focus areas include therapeutic drugs for autoimmune and rare-disease specialty areas along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. Mallinckrodt’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients.

Managed Health Care Associates, Inc. http://www.mhainc.com/
Alyson Aguanno
Director of Specialty Program Development
(973) 805-2940
AAguanno@mhainc.com

Managed Health Care Associates, Inc. (MHA) is a leading health care services and technology company focused on the alternate site healthcare provider. MHA provides expertise in Group Purchasing, Managed Care and Payer Contracting, Reimbursement Management, Specialty Pharmacy Solutions, Pharmaceutical Data Analytics, Consultant Pharmacy Software and Legislative Advocacy. Through the delivery of innovative health care services and solutions, MHA helps members increase operational efficiency, maximize business growth and provide optimum care for their patients. Evidence of MHA’s commitment to the specialty market and ongoing investment in development of new programs for pharmacies is MHA Specialty Pharmacy Solutions. MHA Specialty Pharmacy Solutions is dedicated to optimally position specialty pharmacy members to succeed in an increasingly dynamic health care environment. The MHA Specialty Pharmacy Solutions division helps members navigate the complex specialty pharmacy market. We maximize member pharmacies’ opportunities for success by providing access to products, clinical information, and valuable resources that support improved patient outcomes for our member pharmacies while assisting them with data insights and performance reporting requirements. Our experience in strategic contract implementation enables us to align the resources and expertise of our business partners with ever-expanding opportunities across our vast network of member pharmacies. By supplying our partners with data and analytics that report trends and metrics, we support therapy adherence and contract compliance. For more information, visit www.mhainc.com.

Meda Pharmaceuticals Inc. http://www.medapharma.us
Jeff Hofmeister
Senior Director, Managed Care & Trade Relations
(732) 564-2534
Jeffrey.hofmeister@meda.us

Meda Pharmaceuticals is a specialty pharmaceutical company that markets proprietary drugs in allergy and central nervous system therapies. The goal of the managed healthcare account team is to help managed healthcare organizations improve their level of patient care by providing information on the most current products, disease entities, patients, and cost-benefits.

Michelle Frank

(888) 963-3465
mfrank@medhok.com

MedHOK (Medical House of Knowledge) offers a single integrated platform for Care, Quality and Compliance. Developed for PBMs, Health Plans, and ACOs, MedHOK supports over 26 million covered lives. For Part D Plans, MedHOK’s integrated CMS-compliant modules include: Electronic Prior Authorization, Appeals, Grievances, Complaints Tracking, MTM, Rx Specialty Management and Direct Member Reimbursement.

MedImpact Healthcare Systems, Inc. http://www.medimpact.com
Gordon Romanas

(858) 790-6475
gordon.romanas@medimpact.com

MedImpact Healthcare Systems, Inc. (http://www.medimpact.com), founded in 1989 and headquartered in San Diego, Calif., is a full-service pharmacy benefit management (PBM) company that combines subject matter expertise with innovative technology and services to deliver better healthcare outcomes and improve its clients’ positions in the market. MedImpact provides PBM services to 47 million members of health plans, hospitals and employers in the U.S. and abroad. MedImpact’s model is unique: avoiding conflict of interest by deriving revenue from effectively managing client pharmacy benefits rather than dispensing drugs.

Merck & Co., Inc. http://www.merck.com
Jody A. Shollenberger
Assoc. Director
(267) 305-2481
jody_shollenberger@merck.com

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.

Momenta Pharmaceuticals, Inc www.momentapharma.com
Heather Knapp
Associate General Counsel
(617) 395-2854
Hknapp@momentapharma.com

Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.

Douglas E. Jordan
EVP Managing Director
(212) 672-2424
doug.jordan@mosaic-mmagency.com

Mosaic Group, an FCB Health company, is a full-service healthcare communications agency that specializes in helping brands achieve targeted market access and reimbursement objectives. At Mosaic Group, we drive results for clients and brands by combining innovative payer strategy with on-point creative. From initial engagement to full implementation, the Mosaic Group provides digital expertise across multichannel platforms to bring state-of-the-art strategic and tactical communications to address a brand’s reimbursement challenges and opportunities. Visit http://mosaic-mmagency.com, and follow us on LinkedIn at “Mosaic Group Managed Markets” to see how Mosaic Group can help.

Rameshwari Bhavsar
Account Supervisor
(215) 962-8260
rameshwari.bhavsar@mylan.com

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline.

NaviSync, LLC www.navisyncllc.com
Bill Kelly
Senior Vice President
(973) 845-9970
bill.kelly@navisyncllc.com

The health care environment is becoming more complex, with commercial and government payers attempting to control how health care is practiced and influence market perceptions about products, coverage, or services. NaviSync is a full-service managed markets company providing intelligent sound strategy to increase access to your brand through the utilization of actionable insights gleaned from payers, hospitals, and alternative care settings. Efficiently delivered market intelligence is critical to attaining payer access and achieving commercial success. We tackle access and reimbursement challenges for top-tier pharmaceutical/biotechnology companies, including specialty market products.

Novartis Pharmaceuticals Corporation http://www.pharma.us.novartis.com
Erik Maietta
Convention Manager
(862) 778-2964
erik.maietta@novartis.com

Novartis Pharmaceuticals Corporation is committed to improving health and quality of life by focusing on the discovery, development, manufacture and marketing of innovative, effective and safe prescription medications. Key therapeutic areas include Cardiovascular, Endocrine & Respiratory Diseases, Gastroenterology; Central Nervous System Disorders; Dermatology; Oncology/Hematology; Rheumatism/Bone & Hormone Replacement Therapy and Transplantation. Located in East Hanover, NJ, Novartis Pharmaceuticals is an affiliate of Novartis AG, a world leader in Healthcare in more than 140 countries with core businesses in pharmaceuticals, consumer health, generics, eyecare, and animal health.

Kristie Raker
Director, Professional Association Relations
(609) 786-4595
ksra@novonordisk.com

Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.

Thatcher Sloan
Senior Manager
(202) 679-5280
thatcher.sloan@optimityadvisors.com

In the world of successful business, change is a constant. Optimity Advisors manages and delivers complex business change reliably with deep industry knowledge, information technology, strategic planning, business process re-engineering, organizational change management, and risk mitigation services. We are an operational consultancy that develops fact-based solutions to help transform your business.

Option Care
Todd Beeson
Director, Marketing
(224) 723-2828
todd.beeson@optioncare.com

Option Care is one of the nation’s largest providers of home and alternate treatment site infusion services. The clinically-driven partner that combines the benefits of national scale with local presence to drive the highest quality of care and reduce overall costs. Option Care does this by optimizing the treatment site of care and providing comprehensive, innovative clinical and support services. With nearly 40 years of experience and more than 1,800 clinical experts, including specially trained infusion nurses, infusion pharmacists and registered dietitians, we treat patients of all ages with a wide range of acute and chronic conditions. Contact information: Greg von der Lippe Senior Vice President, Managed Markets M: 847-612-2463 Greg.vonderlippe@optioncare.com

David Calabrese
VP, Clinical Services & Chief Pharmacy Officer
(224) 231-1813
David.calabrese@optum.com

OptumRx® is a pharmacy care services company with a flexible and innovative approach. Our combined company now connects more than 65 million Americans to improved care, lower costs and a better health care experience. Most traditional PBMs focus on distributing prescriptions and managing pharmacy costs. Our diverse and unique resources enable OptumRx to go beyond the prescription — and help our customers and members reduce total health care costs and improve health.

Brand Newland
VP of Business Development
(515) 864-7944
bnewland@outcomesmtm.com

OutcomesMTM®, a Cardinal Health company, is the national leader in the design, delivery and administration of Medication Therapy Management (MTM) programs. The company’s service line helps healthcare purchasers advance patient care and utilization control through patient-friendly Personal Pharmacist™ services, demonstrating the Face-to-Face Difference® for their members. .

John C. Butts
Director, Sales and Public Relations
(215) 937-8073
john.butts@performrx.com

PerformRx, LLC provides innovative, cost-effective pharmacy benefit management services for Medicaid, Medicare, and commercial health plans. Through a distinctive, hightouch approach, PerformRx partners with health plans to improve patient outcomes and financial performance. PerformRx bases its success on a clinical focus hat is driven by cuttingedge, proprietary technology.

John W. Main
Senior Director Field Based Medical
(630) 634-3648
john.main@pfizer.com

As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development. We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most. The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.

Pharmacy Quality Solutions, Inc. http://www.pharmacyquality.com
Todd Sega
Manager of Payer Relations
(919) 864-9756
tsega@pharmacyquality.com

Who We Are Pharmacy Quality Solutions, Inc. (PQS) is a joint venture created to fill the need to connect medication use stakeholders to quality information in a consistent and reliable fashion, allowing them to move more quickly from measurement to improvement. Our hallmark service is EQuIPP, the first national pharmacy quality measurement, benchmarking, and reporting platform for pharmacies and health plans. EQuIPP provides consistent and reliable measurement and reporting on key medication use quality measures, including those addressing medication adherence and patient safety, and makes this measurement available and easily understandable.

Larry Blandford
Executive Vice President, Managing Partner
(908) 470-1780
larry.blandford@precisionformedicine.com

Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. www.precisionformedicine.com
Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry. www.precisionforvalue.com
Precision Advisors combines unrivaled real-world market experience with thought leadership and industry expertise to provide insight, strategy and advice to innovative life science companies. Headquartered in Cambridge, Massachusetts, Precision Advisors’ unmatched team of expert advisors encompass all areas of the commercialization spectrum including strategy consulting, managed markets, health economics, clinical research and analytics. www.pfmadvisors.com

Prime Therapeutics LLC http://www.primetherapeutics.com
Angela Seibert
Sponsorship & Events Manager
(612) 777-6207
aseibert@primetherapeutics.com

Prime Therapeutics is an independent pharmacy benefit manager that is committed to the health of those we serve. Our "people over profits" approach reflects our privately held heritage. We also believe it produces the best results. Our health care system is fragmented. Instead of working together, doctors, pharmacists, and insurers often focus only on their own pieces of the puzzle. Poor communication and lack of coordination cause errors and create gaps in care. Prime has a different view. Because we are collectively owned by non-profit health plans, we never forget that drugs are part of a bigger picture. We exchange pertinent data and insights with health plans and work with them to coordinate across pharmacy and medical benefits. We leverage our unique connections to deliver programs that lead to the best health outcomes.

Purdue Pharma, L.P. http://www.pharma.com
Craig Engesser
Associate Director, Healthcare Alliance Development
(203) 588-8000
craig.engesser@pharma.com

Purdue Pharma L.P. is well known for its pioneering work on persistent pain, a principal cause of human suffering. The company’s leadership and employees are dedicated to providing healthcare professionals, patients and caregivers with effective therapies, and innovative educational resources and tools that support their proper use.

Relypsa, Inc.
Neera Clase
Senior Director, Managed Markets
(650) 421-9640
nclase@relypsa.com

To improve patients’ lives through the discovery, development and delivery of therapeutics that leverage polymer science and other novel approaches.

Ravi Ika
President & CEO
(508) 804-6900
ravi.ika@rxadvance.com

RxAdvance is a national full service PBM (Pharmacy Benefit Manager), bringing superior clinical, pharmacy, and financial outcomes to plan sponsors through Collaborative PBM Cloud. Built on a unified data model and clinical intelligence, RxAdvance’s PBM standard services include Benefit and Formulary Design, Claims Processing, Customer Support Services, Retail Pharmacy Network Management, Clinical Services, and Rebate Management. Our market differentiation includes Drug Utilization Review at Point of Care (PoC) and Point of Sale (PoS), Medication Therapy (MTM) and Adherence Management (MAM), Donut Hole Prediction and Prescription Planner, Optimize Untapped Generics Usage, Prevent Adverse Drug Effects, Fraud, Waste and Abuse Management, Advanced Analytics and Cost Management, Maximize Mail Order Services, and Effective Specialty Management. RxAdvance enables real-time actionable communication between prescriber, pharmacist, patient, and payer. Our best in class People, Process and Technology are for all plan sponsors—health plans, Accountable Care Organizations (ACOs), state Medicaid programs, employer groups, and unions. We provide contractually guaranteed savings in administrative costs, unit costs, and rebate revenues.

William Yoon
National Director, Clinical Development and Medical Affairs
(602) 881-1280
william.yoon@sandoz.com

Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines is core to who we are and what we do, our mission is even greater: We endeavor to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.

James Caro
Senior Director, US Advocacy
(202) 585-3030
james.caro@sanofi.com

Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With approximately 100,000 dedicated professionals in more than 100 countries, Sanofi-aventis is devoted to advancing healthcare around the world. We are committed to maintaining the innovative approach to pharmaceuticals established by our parent company, headquartered in Paris, France. Our U.S. affiliate, with headquarters in Bridgewater, New Jersey, employs approximately 12,000 professionals located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare organization working to meet the needs of physicians and their patients. At sanofi-aventis, each and every day we work for what really matters: health .For more information, visit www.sanofi-aventis.us

Shire US Inc. http://www.shire.com
Edward M. DePaz
VP, Head of Commercial Accounts
(484) 595-8801
edepaz@shire.com

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com.

Sunovion Pharmaceuticals, Inc. http://www.sunovion.com
Melissa Longstreet Kay
Associate Director, Managed Markets Marketing
(508) 357-7710
melissa.longstreet-kay@sunovion.com

We are Sepracor, a research-based pharmaceutical company with a focus on treatments for respiratory and central nervous system. Our robust product pipeline is focused on providing treatments that address large and growing disease states that are principally served by primary care physicians. From insomnia to asthma, to depression and restless legs syndrome, we are seeking ways to improve the lives of the millions of people suffering from these potentially debilitating conditions. The Sepracor Organized Customer Group is dedicated to working with managed care executives to find innovative solutions to improve patient care and support efforts to provide quality health care. The common stock of Sepracor Inc. is traded on the NASDAQ Stock Market under the symbol SEPR.

Supernus Pharmaceuticals Inc http://www.supernus.com
Gary Ellexson
VP, Corporate Accounts
(301) 838-2557
gellexson@supernus.com

With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Taiho Oncology, Inc. www.taihooncology.com
Tim Wert
Senior Director, Market Access
(609) 664-1540
twert@taihooncology.com

Taiho Oncology, Inc. (www.taihooncology.com), a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.

Takeda Pharmaceuticals U.S.A., Inc. http://www.takeda.us/
Mark Gimbert
Director, Regional Accounts
(224) 554-7229
mark.gimbert@takeda.com

Based in Deerfield, IL, Takeda Pharmaceuticals, U.S.A., Inc and Takeda Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, respiratory and immunology, gastroenterology, central nervous system and obesity treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, central nervous system, oncology and other conditions. To learn more about Takeda companies and products, visit www.takeda.com.

Teva Pharmaceuticals http://www.tevausa.com
Travis Kenney
Senior Manager, Health Systems Marketing
(913) 777-3095
travis.kenney@Tevapharm.com

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules, sold in more than 100 countries, and with a direct presence in about 60 countries. Teva's specialty medicine businesses focus on CNS, including pain, respiratory, oncology, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.

Seth Gordon
Managing Partner
(973) 255-9360
sgordon@frontiermmarkets.com

The Access Group is the leading independent strategic health care communications network composed of 7 distinct companies: Bioeclipse, Catalyst Medical Communications, FronTier Managed Markets, Fusion Medical Communications, MedAccess, Promidian, and StrataMed. The firm employs more than 95 health care marketing specialists and senior leaders with experience in management consulting, medical education, marketing communications, managed markets, training, and brand promotion. The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, Los Angeles, San Diego, and San Francisco. To learn more about our company, please visit www.theaccessgp.com or contact Seth Gordon, Managing Partner, at (908) 508-6700.

Trividia Health www.trividiahealth.com
Mary Drew
Senior Marketing Manager, Managed Markets
(954) 332-2168
mdrew@trividiahealth.com

Trividia Health (formerly Nipro Diagnostics, Inc.) is a global consumer health and wellness company based in Fort Lauderdale, Florida and a leading developer, manufacturer and marketer of advanced performance products for people with diabetes, including a broad portfolio of blood glucose monitoring supplies and technologies. Our research and development team remains dedicated to developing products that deliver outstanding performance and value, and continues to look for ways to help people manage diabetes in a way that best fits their individual lifestyle. Our product portfolio features products designed to fit the needs of every person with diabetes. We're committed to continuing to introduce new products; with the ultimate goal of helping the millions of people with diabetes enjoy a better quality of life.

Upsher-Smith Laboratories, Inc. http://www.upsher-smith.com
Mike McBride
AVP, Partner Relations
(763) 315-2173
mike.mcbride@upsher-smith.com

Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals’ lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders. For more information, visit www.upsher-smith.com.

Valeant Pharmaceuticals http://www.valeant.com
Sandra Loreaux
VP of Market Access
(908) 927-1400
Sandra.Loreaux@Valeant.com

Valeant Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to Gastroenterologists and their patients.

Douglas S. Burgoyne
President
(801) 365-0290
DBurgoyne@myvrx.com

Veridicus Health provides comprehensive and customizable pharmacy solutions. We are industry leaders in clinical care management, MTM and PBM services for commercial and Medicare Part D Plans. Veridicus means Speaking Truth. Speaking Truth is our corporate philosophy and exemplifies the type of honest and complete information you will always receive from us. We are committed to providing exemplary service while maintaining lowest net cost. We focus on integrating auxiliary health care services into one cohesive solution, empowering members to make informed decisions regarding their healthcare, and easing your administrative burden.

Rory Davies
Vice President of Clinical Programs
(720) 291-0477
rdavies@welldynerx.com

WellDyneRx is an innovative, full-service prescription benefit manager, servicing its health plan members through a retail network of over 65,000 pharmacies nationwide. Our full-service mail order facilities utilize advanced robotics to accurately fill more than 1 million prescriptions per year.

Xcenda/AmerisourceBergen http://www.amerisourcebergen.com
Matthew Sarnes
Senior Vice President, Xcenda
(727) 771-4100 x4024
msarnes@xcenda.com

Xcenda is a premier full-service consultancy and leading managed markets agency whose experienced consulting team helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to all healthcare stakeholders. For 15 years, Xcenda has been an essential partner, offering both strategic guidance and field support, to global pharmaceutical, device, and diagnostic companies, as well as emerging pre-commercialization phase firms. Clients who partner with Xcenda access marketers, health outcomes researchers, epidemiologists, reimbursement strategists, market research experts, managed care decision makers, and clinicians who bring a breadth of expertise across payer, provider, and patient segments. In addition, as Xcenda is part of AmerisourceBergen Corporation, our clients benefit from greater access to an integrated and comprehensive range of specialty distribution and commercialization support services.

Xerox State Healthcare, LLC www.xerox.com/govhealthcare
Amy Cully
Clinical Pharmacist
(716) 572-5734
Amy.cully@xerox.com

ZS Pharma, Inc. www.zspharma.com
Kevin Norrett
VP Market Access & Commercial Development
(650) 670-8728
knorrett@zspharma.com

ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. We are currently focused on using our proprietary ion­-trap technology to develop new treatments that are focused on addressing unmet needs in the medical community. From manufacturing to technology to people, ZS Pharma is thinking differently about developing therapies to address unmet needs.

Content for class "break" Goes Here